TLSI — TriSalus Life Sciences Balance Sheet
0.000.00%
- $164.91m
- $178.57m
- $29.43m
- 26
- 15
- 63
- 26
Annual balance sheet for TriSalus Life Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | R2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 4.49 | 30.3 | 9.41 | 11.8 | 8.53 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.617 | 1.36 | 1.56 | 3.55 | 5.09 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 6.08 | 35.1 | 17.2 | 20.9 | 20.7 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 1.26 | 1.8 | 3.61 | 3.27 | 2.88 |
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 8.13 | 37.8 | 22 | 24.6 | 24 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 54.7 | 6.37 | 32.4 | 14.7 | 10.2 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 58.3 | 6.93 | 34.3 | 51.7 | 49.9 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | -50.2 | 30.9 | -12.3 | -27.1 | -25.9 |
Total Liabilities & Shareholders' Equity | 8.13 | 37.8 | 22 | 24.6 | 24 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |